Seeking Alpha
20 May 2026, 10:42 UTC · 1d ago
Source · https://seekingalpha.com/article/4906927-nrx-pharmaceuticals-sell-on-zyesaminrx-101-failures-and-depression-market-uncertainty
Read source
Search tags
Story key points
3 claims · impact-rated
NRx Pharmaceuticals (NRXP) has been downgraded from 'Buy' to 'Sell' following clinical trial failures for ZYESAMI and NRX-101. — A rating downgrade paired with clinical trial failures directly impairs the company's valuation and investor confidence.
-0.90The NRX-100 NDA filing for suicidal depression is expected in Q2 2026. — This provides a future catalyst for growth, though it is delayed by over a year.
+0.30The KETAFREE ANDA review is scheduled for July 29, 2026. — This represents a potential revenue stream, but the distant date limits immediate market impact.
+0.20Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company was downgraded from 'Buy' to 'Sell' following clinical trial failures.
No ticker relationship head found.
